Thus, amongst patients with similar clinical presentation where PDAC is being considered as differential diagnosis, serum PTX3 is better than clinically used tumor-marker CEA and is similar in performance to CA19-9 (Fig. 1E–G, Supplementary Table 1) making a case for a prospective cohort study with matched data-points for formal comparison. The gene discussed is PTX3; the disease is neoplasm.